EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of STAT6 Variants on the Response to Proton Pump Inhibitors and Comorbidities in Patients with Eosinophilic Esophagitis

Paula Soria-Chacartegui iD, Marcos Navares-Gómez, Francisca Molina-Jiménez, Emilio J Laserna-Mendieta iD, Laura Arias-González iD, Pedro Majano, Sergio Casabona iD, Alfredo J Lucendo iD, Francisco Abad-Santos iD, Cecilio Santander iD, Pablo Zubiaur iD

International Journal of Molecular Sciences · 26.03.2024 · 25 (7) · 3685

DOI: 10.3390/ijms25073685 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 26.03.2024. Verfasst von Paula Soria-Chacartegui und 10 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology Department, Hospital Universitario de La Princesa, Faculty of Medicine, Universidad Autónoma de Madrid (UAM), 28006 Madrid, Spa…. Hauptthemen laut MEDLINE: Eosinophilic Esophagitis, Enteritis, Eosinophilia, Gastritis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FPI-UAM-2021 predoctoral fellowship, Acción Estratégica en Salud 2017–2020, “Contrato Margarita Salas de la convocatoria para la Recualificación del Sistema Universitario Español” (UAM).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Proton pump inhibitors (PPIs) are the first-line drug for eosinophilic esophagitis (EoE), although it is estimated that there is a lack of histological remission in 50% of patients. This research aimed to identify pharmacogenetic biomarkers predictive of PPI effectiveness and to study their association with disease features. Peak eosinophil count (PEC) and the endoscopic reference score (EREFS) were determined before and after an eight-week PPI course in 28 EoE patients. The impact of the signal transducer and activator of transcription 6 (STAT6), CYP2C19, CYP3A4, CYP3A5, and ABCB1 genetic variations on baseline PEC and EREFS, their reduction and histological response, and on EoE symptoms and comorbidities was analyzed. PEC reduction was higher in omeprazole-treated patients (92.5%) compared to other PPIs (57.9%, p = 0.003). STAT6 rs12368672 (g.18453G>C) G/G genotype showed higher baseline PEC values compared to G/C and C/C genotypes (83.2 vs. 52.9, p = 0.027). EREFS reduction in STAT6 rs12368672 G/G and G/C genotypes was higher than in the C/C genotype (36.7% vs. −75.0% p = 0.011). However, significance was lost after Bonferroni correction. Heartburn incidence was higher in STAT6 rs167769 (g.27148G>A) G/G patients compared to G/A (54.55% vs. 11.77%, p = 0.030). STAT6 rs12368672G>C and rs167769G>A variants might have a relevant impact on EoE status and PPI response. Further research is warranted to clarify the clinical relevance of these variants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Eosinophilic EsophagitisEnteritisEosinophiliaGastritisHumansProton Pump InhibitorsSTAT6 Transcription FactorComorbidity

Stichwörter der Autor:innen

CYP2C19STAT6eosinophilic esophagitispharmacogenetics

Substanzen

Proton Pump InhibitorsSTAT6 Transcription FactorSTAT6 protein, human

Autor:innen und Institutionen

  • Clinical Pharmacology Department, Hospital Universitario de La Princesa, Faculty of Medicine, Universidad Autónoma de Madrid (UAM), 28006 Madrid, Spain.
  • Instituto de Investigación Sanitaria La Princesa (IIS-IP), 28006 Madrid, Spain.
  • Gastroenterology Department, Hospital Universitario de La Princesa, Faculty of Medicine, Universidad Autónoma de Madrid (UAM), 28006 Madrid, Spain.
  • Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, 28029 Madrid, Spain.
  • Gastroenterology Department, Hospital General de Tomelloso, 13700 Ciudad Real, Spain.
  • Instituto de Investigación Sanitaria de Castilla-La Mancha (IDISCAM), 45071 Toledo, Spain.

ORCID-Profile: Paula Soria-Chacartegui, Emilio J Laserna-Mendieta, Laura Arias-González, Sergio Casabona, Alfredo J Lucendo, Francisco Abad-Santos, Cecilio Santander, Pablo Zubiaur

Förderung

  • FPI-UAM-2021 predoctoral fellowship
  • Acción Estratégica en Salud 2017–2020
  • “Contrato Margarita Salas de la convocatoria para la Recualificación del Sistema Universitario Español” (UAM)
  • Instituto de Salud Carlos III (ISCIII, Spain)
  • Asociación Española de Gastroenterología (AEG)
  • Spanish Ministry of Health—Social Services and Equality
  • European Social Fund

Zitieren

APA

Soria-Chacartegui, P., Navares-Gómez, M., Molina-Jiménez, F., Laserna-Mendieta, E. J., Arias-González, L., Majano, P., Casabona, S., Lucendo, A. J., Abad-Santos, F., Santander, C., & Zubiaur, P. (2024). Impact of STAT6 Variants on the Response to Proton Pump Inhibitors and Comorbidities in Patients with Eosinophilic Esophagitis. International Journal of Molecular Sciences, 25(7), 3685. https://doi.org/10.3390/ijms25073685

Vancouver

Soria-Chacartegui P, Navares-Gómez M, Molina-Jiménez F, Laserna-Mendieta EJ, Arias-González L, Majano P, et al. Impact of STAT6 Variants on the Response to Proton Pump Inhibitors and Comorbidities in Patients with Eosinophilic Esophagitis. International Journal of Molecular Sciences. 2024;25(7):3685. doi:10.3390/ijms25073685

BibTeX
@article{SoriaChacartegui2024,
  author = {Soria-Chacartegui, Paula and Navares-Gómez, Marcos and Molina-Jiménez, Francisca and Laserna-Mendieta, Emilio J and Arias-González, Laura and Majano, Pedro and Casabona, Sergio and Lucendo, Alfredo J and Abad-Santos, Francisco and Santander, Cecilio and Zubiaur, Pablo},
  title = {Impact of STAT6 Variants on the Response to Proton Pump Inhibitors and Comorbidities in Patients with Eosinophilic Esophagitis},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {7},
  pages = {3685},
  doi = {10.3390/ijms25073685}
}
Kostenlos starten →